vs
Adaptive Biotechnologies Corp（ADPT）与Ranger Energy Services, Inc.（RNGR）财务数据对比。点击上方公司名可切换其他公司
Ranger Energy Services, Inc.的季度营收约是Adaptive Biotechnologies Corp的2.0倍（$142.2M vs $71.7M），Ranger Energy Services, Inc.净利率更高（2.3% vs -18.9%，领先21.2%），Adaptive Biotechnologies Corp同比增速更快（51.0% vs -0.6%），Ranger Energy Services, Inc.自由现金流更多（$17.1M vs $1.4M），过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs 1.9%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
Ranger Energy Services是北美领先的陆上油田服务提供商，为上游油气运营商提供完井、修井、钻机作业及产能优化等全套解决方案，业务主要覆盖美国本土的页岩和致密资源开采作业区。
ADPT vs RNGR — 直观对比
营收规模更大
RNGR
是对方的2.0倍
$71.7M
营收增速更快
ADPT
高出51.7%
-0.6%
净利率更高
RNGR
高出21.2%
-18.9%
自由现金流更多
RNGR
多$15.7M
$1.4M
两年增速更快
ADPT
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $142.2M |
| 净利润 | $-13.6M | $3.2M |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | 2.3% |
| 净利率 | -18.9% | 2.3% |
| 营收同比 | 51.0% | -0.6% |
| 净利润同比 | 59.7% | -44.8% |
| 每股收益（稀释后） | $-0.08 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTRNGR
| Q4 25 | $71.7M | $142.2M | ||
| Q3 25 | $94.0M | $128.9M | ||
| Q2 25 | $58.9M | $140.6M | ||
| Q1 25 | $52.4M | $135.2M | ||
| Q4 24 | $47.5M | $143.1M | ||
| Q3 24 | $46.4M | $153.0M | ||
| Q2 24 | $43.2M | $138.1M | ||
| Q1 24 | $41.9M | $136.9M |
净利润ADPTRNGR
| Q4 25 | $-13.6M | $3.2M | ||
| Q3 25 | $9.5M | $1.2M | ||
| Q2 25 | $-25.6M | $7.3M | ||
| Q1 25 | $-29.9M | $600.0K | ||
| Q4 24 | $-33.7M | $5.8M | ||
| Q3 24 | $-32.1M | $8.7M | ||
| Q2 24 | $-46.2M | $4.7M | ||
| Q1 24 | $-47.5M | $-800.0K |
毛利率ADPTRNGR
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTRNGR
| Q4 25 | -17.8% | 2.3% | ||
| Q3 25 | 10.9% | 2.0% | ||
| Q2 25 | -42.5% | 6.1% | ||
| Q1 25 | -56.4% | 0.7% | ||
| Q4 24 | -71.3% | 6.2% | ||
| Q3 24 | -70.3% | 8.4% | ||
| Q2 24 | -109.6% | 5.3% | ||
| Q1 24 | -116.5% | -0.4% |
净利率ADPTRNGR
| Q4 25 | -18.9% | 2.3% | ||
| Q3 25 | 10.2% | 0.9% | ||
| Q2 25 | -43.5% | 5.2% | ||
| Q1 25 | -56.9% | 0.4% | ||
| Q4 24 | -71.0% | 4.1% | ||
| Q3 24 | -69.1% | 5.7% | ||
| Q2 24 | -107.0% | 3.4% | ||
| Q1 24 | -113.5% | -0.6% |
每股收益（稀释后）ADPTRNGR
| Q4 25 | $-0.08 | $0.14 | ||
| Q3 25 | $0.06 | $0.05 | ||
| Q2 25 | $-0.17 | $0.32 | ||
| Q1 25 | $-0.20 | $0.03 | ||
| Q4 24 | $-0.22 | $0.24 | ||
| Q3 24 | $-0.22 | $0.39 | ||
| Q2 24 | $-0.31 | $0.21 | ||
| Q1 24 | $-0.33 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $10.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $218.8M | $300.1M |
| 总资产 | $512.7M | $419.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTRNGR
| Q4 25 | $70.5M | $10.3M | ||
| Q3 25 | $55.0M | $45.2M | ||
| Q2 25 | $43.2M | $48.9M | ||
| Q1 25 | $50.6M | $40.3M | ||
| Q4 24 | $47.9M | $40.9M | ||
| Q3 24 | $38.1M | $14.8M | ||
| Q2 24 | $59.8M | $8.7M | ||
| Q1 24 | $71.2M | $11.1M |
总债务ADPTRNGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
股东权益ADPTRNGR
| Q4 25 | $218.8M | $300.1M | ||
| Q3 25 | $204.4M | $270.0M | ||
| Q2 25 | $179.7M | $276.9M | ||
| Q1 25 | $190.4M | $272.6M | ||
| Q4 24 | $202.7M | $273.8M | ||
| Q3 24 | $223.8M | $267.6M | ||
| Q2 24 | $241.6M | $260.5M | ||
| Q1 24 | $274.9M | $261.7M |
总资产ADPTRNGR
| Q4 25 | $512.7M | $419.3M | ||
| Q3 25 | $490.6M | $372.8M | ||
| Q2 25 | $496.6M | $381.7M | ||
| Q1 25 | $510.9M | $376.5M | ||
| Q4 24 | $539.4M | $381.6M | ||
| Q3 24 | $558.5M | $373.9M | ||
| Q2 24 | $584.9M | $359.6M | ||
| Q1 24 | $620.3M | $355.5M |
负债/权益比ADPTRNGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $24.1M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $17.1M |
| 自由现金流率自由现金流/营收 | 2.0% | 12.0% |
| 资本支出强度资本支出/营收 | 0.9% | 4.9% |
| 现金转化率经营现金流/净利润 | — | 7.53× |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $42.9M |
8季度趋势，按日历期对齐
经营现金流ADPTRNGR
| Q4 25 | $2.1M | $24.1M | ||
| Q3 25 | $-7.1M | $13.6M | ||
| Q2 25 | $-12.4M | $20.7M | ||
| Q1 25 | $-28.5M | $10.6M | ||
| Q4 24 | $-12.5M | $32.7M | ||
| Q3 24 | $-27.1M | $17.7M | ||
| Q2 24 | $-17.3M | $22.1M | ||
| Q1 24 | $-38.4M | $12.0M |
自由现金流ADPTRNGR
| Q4 25 | $1.4M | $17.1M | ||
| Q3 25 | $-7.5M | $8.0M | ||
| Q2 25 | $-13.1M | $14.4M | ||
| Q1 25 | $-29.7M | $3.4M | ||
| Q4 24 | $-12.6M | $27.3M | ||
| Q3 24 | $-27.4M | $10.8M | ||
| Q2 24 | $-19.0M | $6.8M | ||
| Q1 24 | $-39.9M | $5.5M |
自由现金流率ADPTRNGR
| Q4 25 | 2.0% | 12.0% | ||
| Q3 25 | -8.0% | 6.2% | ||
| Q2 25 | -22.2% | 10.2% | ||
| Q1 25 | -56.7% | 2.5% | ||
| Q4 24 | -26.5% | 19.1% | ||
| Q3 24 | -59.0% | 7.1% | ||
| Q2 24 | -44.1% | 4.9% | ||
| Q1 24 | -95.2% | 4.0% |
资本支出强度ADPTRNGR
| Q4 25 | 0.9% | 4.9% | ||
| Q3 25 | 0.4% | 4.3% | ||
| Q2 25 | 1.1% | 4.5% | ||
| Q1 25 | 2.4% | 5.3% | ||
| Q4 24 | 0.2% | 3.8% | ||
| Q3 24 | 0.7% | 4.5% | ||
| Q2 24 | 4.0% | 11.1% | ||
| Q1 24 | 3.6% | 4.7% |
现金转化率ADPTRNGR
| Q4 25 | — | 7.53× | ||
| Q3 25 | -0.75× | 11.33× | ||
| Q2 25 | — | 2.84× | ||
| Q1 25 | — | 17.67× | ||
| Q4 24 | — | 5.64× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | — | 4.70× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
